{"podcast":{"title":"Business Of Biotech","slug":"business-of-biotech-123501","podcast_index_feed_id":123501,"rss_url":"https://rss.buzzsprout.com/1011661.rss","website_url":"https://www.bioprocessonline.com/solution/the-business-of-biotech-podcast","image_url":"https://storage.buzzsprout.com/35u0bccu9j9xpr9zrrjias54otax?.jpg","author":"Ben Comer","episode_count":310,"summary":"The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.","last_synced_at":"2026-06-08T22:18:30.179389+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501"},"episode":{"title":"Building A Cancer Pipeline In A Molecule With Actuate Therapeutics' Dan Schmitt","slug":"building-a-cancer-pipeline-in-a-molecule-with-actuate-therapeutics-dan-schmitt","published_at":"2025-12-01T11:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/building-a-cancer-pipeline-in-a-molecule-with-actuate-therapeutics-dan-schmitt","show_page_url":"https://stenobird.com/podcast/business-of-biotech-123501","url":"https://www.buzzsprout.com/1011661/episodes/18250776-building-a-cancer-pipeline-in-a-molecule-with-actuate-therapeutics-dan-schmitt.mp3","audio_url":"https://www.buzzsprout.com/1011661/episodes/18250776-building-a-cancer-pipeline-in-a-molecule-with-actuate-therapeutics-dan-schmitt.mp3","summary":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Dan Schmitt, President and CEO at Actuate Therapeutics, talks about building a company around elraglusib, a GSK-3β inhibitor for cancer. Dan describes his fast-fail approach to early product testing and development, using basket trials to evaluate chemotherapy combinations, and choosing pancreatic cancer as a lead program. He also talks about surviving an IPO during a brutal funding cycl...","meta_description":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Dan Schmitt, President and CEO at Actuate Therap…","key_points":[],"chapters":[],"topics":[],"duration_seconds":3085,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/building-a-cancer-pipeline-in-a-molecule-with-actuate-therapeutics-dan-schmitt/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/building-a-cancer-pipeline-in-a-molecule-with-actuate-therapeutics-dan-schmitt.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}